Chorioamnionitis is a significant complication of PPROM, affecting approximately 40% of cases and dramatically increasing the risk of neonatal cerebral palsy, sepsis, and chronic lung disease. Despite advancements in neonatal intensive care, the prevention of ascending infection remains a cornerstone of obstetric practice. This study addresses a critical gap in current guidelines regarding the optimal antibiotic combinations for maximizing the latency period without increasing maternal risks. By identifying a more effective prophylactic strategy, this research contributes to the reduction of preterm birth complications and healthcare costs associated with prolonged NRCU stays. The findings are particularly relevant for clinicians seeking to balance the risks of expectant management with the hazards of neonatal prematurity, providing a robust framework for evidence-based decision-making in high-risk obstetric units and improving global maternal health outcomes.
The study aims to evaluate the efficacy of an enhanced dual-antibiotic prophylaxis protocol in reducing the incidence of clinical chorioamnionitis and prolonging the latency period in patients presenting with preterm premature rupture of membranes.
A randomized controlled trial was conducted involving 640 singleton pregnancies diagnosed with PPROM between 24 and 34 weeks of gestation. Participants were divided into two groups: Group A (n=320) received the standard 7-day course of ampicillin and erythromycin, while Group B (n=320) received an augmented regimen of intravenous ampicillin-sulbactam followed by oral amoxicillin and clarithromycin. The primary endpoint was the incidence of clinical chorioamnionitis, defined by Gibbs’ criteria. Secondary endpoints included the latency period (days from PPROM to delivery), neonatal sepsis, and respiratory distress syndrome (RDS). Maternal blood samples were collected bi-weekly for C-reactive protein (CRP) and white blood cell (WBC) counts. Placental histopathology was performed post-delivery to confirm subclinical chorioamnionitis. Statistical analysis was performed using the Chi-square test for categorical variables and the Mann-Whitney U test for continuous variables, with significance set at p < 0.05.
In the augmented regimen group (Group B), the incidence of clinical chorioamnionitis was significantly lower at 12.5% compared to 21.8% in the standard group (Group A) (OR 0.51, 95% CI 0.34–0.78, p=0.002). The median latency period was significantly longer in Group B (8.4 days) than in Group A (5.2 days, p<0.001). Neonatal outcomes showed a marked improvement in Group B, with a lower rate of early-onset neonatal sepsis (6.8% vs 14.1%, p=0.003) and a reduction in the incidence of Grade III/IV intraventricular hemorrhage (3.1% vs 7.5%, p=0.012). Histopathological chorioamnionitis was confirmed in 28.4% of Group B placentas compared to 42.6% in Group A (p<0.001). Maternal CRP levels remained significantly lower in Group B throughout the latency period (mean 8.2 mg/L vs 14.5 mg/L, p=0.005). No significant differences were noted in maternal adverse effects between the two protocols, confirming the safety of the augmented antibiotic approach.
The implementation of an augmented antibiotic regimen in the management of PPROM significantly reduces the risk of maternal chorioamnionitis and improves neonatal survival rates by extending the gestational period. The reduction in neonatal sepsis and ICH underscores the importance of stringent antimicrobial stewardship and early intervention in cases of membrane rupture. Furthermore, the correlation between reduced maternal CRP levels and improved neonatal outcomes suggests that inflammatory monitoring can serve as a predictive tool for timing delivery. These findings advocate for a standardized, aggressive prophylactic approach in maternal-fetal medicine to minimize the sequelae of intrauterine infection. Future research should focus on the long-term neurodevelopmental outcomes of children born under these enhanced protocols to fully validate the clinical benefits of prolonged latency.